Financial Survey: Cerus Corporation (CERS) vs. The Competition

Cerus Corporation (NASDAQ: CERS) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it compare to its competitors? We will compare Cerus Corporation to similar companies based on the strength of its profitability, earnings, risk, valuation, institutional ownership, analyst recommendations and dividends.

Risk and Volatility

Cerus Corporation has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, Cerus Corporation’s competitors have a beta of 0.96, indicating that their average stock price is 4% less volatile than the S&P 500.

Insider and Institutional Ownership

55.6% of Cerus Corporation shares are held by institutional investors. Comparatively, 42.4% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 7.4% of Cerus Corporation shares are held by insiders. Comparatively, 11.4% of shares of all “Medical Devices & Implants” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Cerus Corporation and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cerus Corporation 0 0 4 0 3.00
Cerus Corporation Competitors 109 726 1020 10 2.50

Cerus Corporation currently has a consensus target price of $7.00, suggesting a potential upside of 91.00%. As a group, “Medical Devices & Implants” companies have a potential upside of 6.01%. Given Cerus Corporation’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Cerus Corporation is more favorable than its competitors.

Earnings and Valuation

This table compares Cerus Corporation and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Cerus Corporation $39.28 million -$62.90 million -6.15
Cerus Corporation Competitors $1.67 billion $207.58 million 74.46

Cerus Corporation’s competitors have higher revenue and earnings than Cerus Corporation. Cerus Corporation is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Cerus Corporation and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cerus Corporation -159.35% -142.18% -67.72%
Cerus Corporation Competitors -101.83% -92.87% -30.39%

Summary

Cerus Corporation competitors beat Cerus Corporation on 7 of the 12 factors compared.

Cerus Corporation Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company’s INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company’s INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply